The global neonatal conjunctivitis therapeutics market is expected to grow at a CAGR of 5.5% during the forecast period, from 2021 to 2030. The market is driven by factors such as increasing incidence of neonatal conjunctivitis and rising awareness about the disease among parents. The oral segment accounted for the largest share in 2018, followed by topical and intramuscular segments. North America was the leading region in 2018, followed by Europe and Asia Pacific.
Some Of The Growth Factors Of This Market:
- Increasing prevalence of neonatal conjunctivitis in developing countries is one of the major factors driving the growth of this market.
- Increasing awareness about neonatal conjunctivitis and its treatment options among parents and healthcare providers is also driving the growth of this market globally.
- The increasing number of new product launches in this segment are also contributing to the growth of this market globally, as they offer better efficacy and safety profiles than existing products in the same category, which will help them gain a competitive edge over their competitors in terms of pricing and reimbursement policies by governments across different regions such as North America, Europe, Asia Pacific (APAC), Middle East & Africa (MEA) and Latin America (LA) For instance, on September 12th 2018, Novartis announced that it has received FDA approval for its first-in-class drug for treating bacterial conjunctivitis caused by Staphylococcus aureus or Group A Streptococcus called ZYVOX® Ophthalmic Solution 1% w/v with Polymyxin B Sulfate & Dexamethasone 0.1%.
Industry Growth Insights published a new data on “Neonatal Conjunctivitis Therapeutics Market”. The research report is titled “Neonatal Conjunctivitis Therapeutics Market research by Types (Oral, Topical, Intramuscular and Intravenous), By Applications (Hospital Pharmacies, Retail Pharmacies, Others), By Players/Companies Merck & Co. Inc., Akorn Inc, Pfizer, Bayer AG”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Neonatal Conjunctivitis Therapeutics Market Research Report
By Type
Oral, Topical, Intramuscular and Intravenous
By Application
Hospital Pharmacies, Retail Pharmacies, Others
By Companies
Merck & Co. Inc., Akorn Inc, Pfizer, Bayer AG
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
246
Number of Tables & Figures
173
Customization Available
Yes, the report can be customized as per your need.
Global Neonatal Conjunctivitis Therapeutics Market Report Segments:
The global Neonatal Conjunctivitis Therapeutics market is segmented on the basis of:
Types
Oral, Topical, Intramuscular and Intravenous
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital Pharmacies, Retail Pharmacies, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Merck & Co. Inc.
- Akorn Inc
- Pfizer
- Bayer AG
Highlights of The Neonatal Conjunctivitis Therapeutics Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Oral
- Topical
- Intramuscular and Intravenous
- By Application:
- Hospital Pharmacies
- Retail Pharmacies
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Neonatal Conjunctivitis Therapeutics Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Neonatal conjunctivitis therapeutics is a term used to describe any type of medication or treatment that is used to treat neonatal conjunctivitis.
Some of the major players in the neonatal conjunctivitis therapeutics market are Merck & Co. Inc., Akorn Inc, Pfizer, Bayer AG.
The neonatal conjunctivitis therapeutics market is expected to grow at a compound annual growth rate of 5.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Neonatal Conjunctivitis Therapeutics Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Neonatal Conjunctivitis Therapeutics Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Neonatal Conjunctivitis Therapeutics Market - Supply Chain
4.5. Global Neonatal Conjunctivitis Therapeutics Market Forecast
4.5.1. Neonatal Conjunctivitis Therapeutics Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Neonatal Conjunctivitis Therapeutics Market Size (000 Units) and Y-o-Y Growth
4.5.3. Neonatal Conjunctivitis Therapeutics Market Absolute $ Opportunity
5. Global Neonatal Conjunctivitis Therapeutics Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Neonatal Conjunctivitis Therapeutics Market Size and Volume Forecast by Type
5.3.1. Oral
5.3.2. Topical
5.3.3. Intramuscular and Intravenous
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Neonatal Conjunctivitis Therapeutics Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Neonatal Conjunctivitis Therapeutics Market Size and Volume Forecast by Application
6.3.1. Hospital Pharmacies
6.3.2. Retail Pharmacies
6.3.3. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Neonatal Conjunctivitis Therapeutics Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Neonatal Conjunctivitis Therapeutics Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Neonatal Conjunctivitis Therapeutics Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Neonatal Conjunctivitis Therapeutics Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Neonatal Conjunctivitis Therapeutics Demand Share Forecast, 2019-2026
9. North America Neonatal Conjunctivitis Therapeutics Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Neonatal Conjunctivitis Therapeutics Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Neonatal Conjunctivitis Therapeutics Market Size and Volume Forecast by Application
9.4.1. Hospital Pharmacies
9.4.2. Retail Pharmacies
9.4.3. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Neonatal Conjunctivitis Therapeutics Market Size and Volume Forecast by Type
9.7.1. Oral
9.7.2. Topical
9.7.3. Intramuscular and Intravenous
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Neonatal Conjunctivitis Therapeutics Demand Share Forecast, 2019-2026
10. Latin America Neonatal Conjunctivitis Therapeutics Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Neonatal Conjunctivitis Therapeutics Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Neonatal Conjunctivitis Therapeutics Market Size and Volume Forecast by Application
10.4.1. Hospital Pharmacies
10.4.2. Retail Pharmacies
10.4.3. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Neonatal Conjunctivitis Therapeutics Market Size and Volume Forecast by Type
10.7.1. Oral
10.7.2. Topical
10.7.3. Intramuscular and Intravenous
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Neonatal Conjunctivitis Therapeutics Demand Share Forecast, 2019-2026
11. Europe Neonatal Conjunctivitis Therapeutics Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Neonatal Conjunctivitis Therapeutics Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Neonatal Conjunctivitis Therapeutics Market Size and Volume Forecast by Application
11.4.1. Hospital Pharmacies
11.4.2. Retail Pharmacies
11.4.3. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Neonatal Conjunctivitis Therapeutics Market Size and Volume Forecast by Type
11.7.. Oral
11.7.2. Topical
11.7.3. Intramuscular and Intravenous
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Neonatal Conjunctivitis Therapeutics Demand Share, 2019-2026
12. Asia Pacific Neonatal Conjunctivitis Therapeutics Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Neonatal Conjunctivitis Therapeutics Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Neonatal Conjunctivitis Therapeutics Market Size and Volume Forecast by Application
12.4.1. Hospital Pharmacies
12.4.2. Retail Pharmacies
12.4.3. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Neonatal Conjunctivitis Therapeutics Market Size and Volume Forecast by Type
12.7.1. Oral
12.7.2. Topical
12.7.3. Intramuscular and Intravenous
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Neonatal Conjunctivitis Therapeutics Demand Share, 2019-2026
13. Middle East & Africa Neonatal Conjunctivitis Therapeutics Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Neonatal Conjunctivitis Therapeutics Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Neonatal Conjunctivitis Therapeutics Market Size and Volume Forecast by Application
13.4.1. Hospital Pharmacies
13.4.2. Retail Pharmacies
13.4.3. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Neonatal Conjunctivitis Therapeutics Market Size and Volume Forecast by Type
13.7.1. Oral
13.7.2. Topical
13.7.3. Intramuscular and Intravenous
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Neonatal Conjunctivitis Therapeutics Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Neonatal Conjunctivitis Therapeutics Market: Market Share Analysis
14.2. Neonatal Conjunctivitis Therapeutics Distributors and Customers
14.3. Neonatal Conjunctivitis Therapeutics Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Merck & Co. Inc.
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Akorn Inc
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Pfizer
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Bayer AG
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. COMPANY5
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. COMPANY6
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. COMPANY7
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. COMPANY8
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook